Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg)
in a double-blind comparison with placebo in the management of patients with primary
hypercholesterolemia. The main objective is to evaluate the effects of AVE5530 on LDL-C level
reduction as adjunct to a controlled diet. The effects of AVE5530 on other lipid parameters
will be assessed as secondary objectives.